Dermatology and Skin Cancer Center

Dermatology and Skin Cancer Center provides specialized dermatological services, focusing on skin cancer treatments, general dermatology, and cosmetic procedures, improving skin health and aesthetics for a diverse clientele. Dermatology and Skin Cancer Center operates within the U. S. Dermatology Partners network, delivering essential dermatological care.

Founded in 1987, the company is headquartered in Leawood, US. In 2014, it became part of U. S. Dermatology Partners through an acquisition facilitated by Candescent Partners, Eagle Private Capital, and Harbert Management Corporation.

U. S. Dermatology Partners, through its Dermatology & Skin Cancer Centers, delivers a comprehensive range of dermatological services and treatments catering to various skin conditions and cosmetic needs. The company's core offerings include skin cancer treatments, general dermatology services, and an expansive array of cosmetic procedures, such as Botox, dermal fillers, chemical peels, and laser therapies.

These services aim to address common skin issues, including acne, eczema, psoriasis, and various forms of skin cancer, while also providing aesthetic enhancements to improve patients' overall appearance and confidence. The company serves a diverse clientele, including individuals from infants to seniors, across several geographical markets, including but not limited to Texas, Kansas, Missouri, and Arizona, ensuring access to quality dermatological care in both urban and suburban settings. U. S.

Dermatology Partners generates revenue through a structured model that encompasses direct-to-consumer transactions for their dermatological and cosmetic services. Patients typically engage with the company for consultations, treatments, and ongoing skin care management, often facilitated through scheduled appointments or telehealth services. Revenue is derived from various treatments, with specific procedures priced according to their complexity and the materials used, including flagship offerings such as Mohs micrographic surgery and aesthetic enhancements like Juvederm and CoolSculpting. The company operates on a fee-for-service basis, ensuring transparency in pricing for both medical and cosmetic procedures, which enhances patient trust and satisfaction.

This structured approach enables the firm to maintain strong relationships with patients while effectively managing service delivery and operational efficiency. The company plans to utilize recent funding from its last deal on May 30, 2014, for strategic growth initiatives. U. S.

Dermatology Partners is focusing on expanding its services into new geographic markets, including regions in the southeastern United States, by the end of 2025. Additionally, the company is enhancing its offerings by developing new products, with a focus on advanced cosmetic procedures set to launch in 2024, which align with their goal of broadening their service portfolio and improving patient outcomes.